# XELOX for Metastatic Breast Cancer

> **NCT00204776** · PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 37 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Capecitabine and Oxaliplatin

## Key facts

- **NCT ID:** NCT00204776
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2019-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00204776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00204776, "XELOX for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00204776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*